



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

AUG 29 2001

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Dr. Yi Chen, RAC  
Director of Regulatory Affairs and  
Quality Assurance  
VidaMed®, Inc.  
46107 Landing Parkway  
Fremont, California 94538

Re: K011787  
Precision™ TUNA® Office System with Model 6800 Cartridge, Model 6198 Handle,  
Model 7800 RF Generator (with no rectal temperature monitoring tape)  
21 CFR 876.4300/Procode: 78 KNS  
21 CFR 878.4400/Procode: 78 GEI  
Regulatory Class: II  
Dated: June 7, 2001  
Received: June 8, 2001

Dear Dr. Chen:

This letter corrects our substantially equivalent letter of July 6, 2001, regarding the Precision™ TUNA® Office System with Model 6800 Cartridge, Model 6198 Handle, Model 7800 RF Generator (with no rectal temperature monitoring tape) which also listed in error the Cobra Handpiece as an component.

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval) it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General (QS) regulation (21 CFR Part 820) and that, through periodic QS inspections, FDA will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, the Food and Drug Administration (FDA) may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 – Dr. Yi Chen

This letter will allow you to continue marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4616. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at their toll free number (800) 638-2041 or at (301) 443-6597 or at its Internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,

A handwritten signature in cursive script that reads "Nancy C. Brogdon".

Nancy C. Brogdon  
Director, Division of Reproductive, Abdominal,  
and Radiological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

INDICATIONS FOR USE

Page 1 of 1

510 (k) Number (if known): K011787

Device Name: TUNA Office System

Indications For Use:

The TUNA Office System is intended for use in the treatment of symptoms due to urinary outflow obstruction secondary to Benign Prostatic Hyperplasia (BPH) in men over the age of 50 with prostate sizes between 20 and 50 cc.

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Jane C. Brogdon  
(Division Sign-Off)  
Division of Reproductive, Abdominal, ENT,  
and Radiological Devices  
510(k) Number K011787

Prescription Use ☒  
(Per 21 CFR 801.109)

OR

Over-The-Counter Use ☐

(Optional Format 1-2-96)

00004